New drug combo shows promise against aggressive breast cancer
NCT ID NCT07054242
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, given before surgery to people with stage II or III triple-negative breast cancer (TNBC). The goal is to see if this treatment can eliminate all signs of cancer by the time of surgery. About 52 participants who have not had prior treatment will receive the drugs for 8 to 18 weeks, then undergo surgery. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Breast Surgery, Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.